benztropine
Adjunctive therapy • Brands: Cogentin
Last reviewed: 2025-12-30
General information
- Class: Adjunctive therapy
- Common US brands: Cogentin
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-30
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Anticholinergic (antimuscarinic) antiparkinson agent used for parkinsonism and to control extrapyramidal reactions caused by neuroleptic drugs (except tardive dyskinesia). In psychiatric practice it is often used short term for drug-induced parkinsonism or acute dystonia, balancing symptomatic benefit against anticholinergic adverse effects (confusion, constipation, urinary retention).
Metabolism & Half‑life
- Metabolism: Hepatic metabolism (extent not well characterized in current labeling) (label/clinical).
- Half‑life: —
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- Benztropine mesylate tablets prescribing information — DailyMed (2025)
- Recognition and Management of Antipsychotic-Induced Parkinsonism in Older Adults A Narrative Review — Medicines (2021)
- Managing Antipsychotic-Induced Acute and Tardive Dystonia — Drug Safety (1998)
- Anticholinergic Burden and Cognitive Performance in Patients With Schizophrenia A Systematic Literature Review — Frontiers in Psychiatry (2021)
- AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology — Pharmacopsychiatry (2018)